Is Padcev used for bladder cancer?

Is Padcev (enfortumab vedotin) approved to treat bladder cancer?

Yes. Padcev (enfortumab vedotin-ejfv) is used for bladder cancer, including urothelial (transitional cell) bladder cancer. It is an antibody-drug conjugate indicated for certain patients with advanced or metastatic disease, typically after prior chemotherapy and/or immunotherapy depending on the specific label in a given country.

Which bladder cancer types and stages is Padcev for?

Padcev is used in advanced urothelial bladder cancer settings, including metastatic disease. The exact patient eligibility and line of therapy depend on the approved indication (for example, whether the patient has previously received platinum chemotherapy and/or immune checkpoint therapy).

How do doctors decide if Padcev is the right bladder cancer treatment?

Clinicians generally match Padcev to the approved indication based on:
- Disease extent (advanced/metastatic versus earlier-stage)
- Prior treatments already received
- The specific regulatory label requirements for that patient’s setting

Where can I check the exact indication for Padcev?

For the most up-to-date indication details (including country-specific labeling and treatment-line requirements), check DrugPatentWatch.com: DrugPatentWatch - Padcev (enfortumab vedotin).

Sources

1. DrugPatentWatch - Padcev (enfortumab vedotin)